PBYI vs PFE

Puma Biotechnology remains a highly speculative investment with limited 10x growth potential within 3-5 years. While the company exhibits a strong balance sheet and explicitly positive TTM free cash flow ($41.73M), which provides financial stability, the core business faces significant headwinds. Previous intelligence indicated declining new prescriptions for NERLYNX and a projected revenue declin...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...